PHA-793887

3-甲基-N-[1,4,5,6-四氢-6,6-二甲基-5-[(1-甲基-4-哌啶基)甲酰基]吡咯并[3,4-C]吡唑-3-基]丁酰胺

CS-350;PHA-793887;PHA793887;3-甲基-N-[1,4,5,6-四氢-6,6-二甲基-5-[(1-甲基-4-哌啶基)甲酰基]吡咯并[3,4-C]吡唑-3-基]丁酰胺

CYT997

N-乙基-N'-[2-甲氧基-4-[5-甲基-4-[[(1S)-1-(3-吡啶基)丁基]氨基]-2-嘧啶基]苯基]脲

N-乙基-N'-[2-甲氧基-4-[5-甲基-4-[[(1S)-1-(3-吡啶基)丁基]氨基]-2-嘧啶基]苯基]脲;CS-347;CYT997;CYT-997;CYT 997;LEXIBULIN.;N-ETHYL-N'-[2-METHOXY-4-[5-METHYL-4-[[(1S)-1-(3-PYRIDINYL)BUTYL]AMINO]-2-PYRIMIDINYL]PHENYL]UREA;CYT997

6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide

6-氨基-N-[3-[4-(4-吗啉基)吡啶并[3',2':4,5]呋喃并[3,2-D]嘧啶-2-基]苯基]-3-吡啶甲酰胺

CS-335;6-氨基-N-[3-[4-(4-吗啉基)吡啶并[3',2':4,5]呋喃并[3,2-D]嘧啶-2-基]苯基]-3-吡啶甲酰胺

CUDC-101

7-[[4-(3-乙炔基苯基氨基)-7-甲氧基喹唑啉-6-基]氧基]-N-羟基庚酰胺

CUDC101;CUDC 101;CURIS;7-[[4-(3-乙炔基苯基氨基)-7-甲氧基喹唑啉-6-基]氧基]-N-羟基庚酰胺

PF 670462

4-[1-环己基-4-(4-氟苯基)-1H-咪唑-5-基]-2-嘧啶胺盐酸盐

4-[1-环己基-4-(4-氟苯基)-1H-咪唑-5-基]-2-嘧啶胺盐酸盐;PF 67046;CS-318

KW-2478

KW-2478

KW-2478;2-Ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]benzoyl]benzeneacetamide;2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-N,N-bis(2-methoxyethyl)acetamide;2-(2-ethyl-3,5-dihydroxy-6-(3-methoxy-4-(2-morpholinoethoxy)benzoyl)phenyl)-N,N-bis(2-methoxyethyl)acetamide;2-Ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]benzoyl]benzeneacetamide KW2478;2-(2-Ethyl-3,5-dihydroxy-6-(3-methoxy-4-(2-morpholinoethoxy)benzoyl)phenyl)-N,N-bis(2-methoxye

MLN-8237

4-[[9-氯-7-(2-氟-6-甲氧基苯基)-5H-嘧啶并[5,4-D][2]苯并氮杂卓-2-基]氨基]-2-甲氧基苯甲酸

4-[[9-氯-7-(2-氟-6-甲氧基苯基)-5H-嘧啶并[5,4-D][2]苯并氮杂卓-2-基]氨基]-2-甲氧基苯甲酸;阿立塞替

MK-2206 di hydrochloride

MK-2206 2HCl

8-[4-(1-氨基环丁基)苯基]-9-苯基-1,2,4-三...;MK-2206 2HCL;MK2206;CS-260;MK 2206 2HCL;MK2206 2HCL;MK-2206 DIHYDROCHLORIDE;MK2206 DIHYDROCHLORIDE;(8-[4-(1-氨基环丁基)苯基]-9-苯基-2H-[1,4]三唑并[3,4-F][1,6]萘啶-3-酮)二盐酸盐;MK-2206 二盐酸盐,一种变构 AKT 抑制剂;MK 2206 2HCL;MK2206 2HCL;8-[4-(1-氨基环丁基)苯基]-9-苯基-1,4-三唑并[3,6]萘啶-3(2H)-酮二盐酸盐

ADX-47273

(S)-(4-氟苯基)-{3-[3-(4-氟苯基)-[1,2,4]二唑-5-基]哌啶-1-基}甲酮

(S)-(4-氟苯基)-3-[3-(4-氟苯基)-[1,2,4]二唑-5-基]哌啶-1-基甲酮>98%;(S)-(4-氟苯基)-{3-[3-(4-氟苯基)-[1,4]二唑-5-基]哌啶-1-基}甲酮;CS-221;ADX-47273;ADX47273;(4-氟苯基)[(3S)-3-[3-(4-氟苯基)-1,4-噁二唑-5-基]-1-哌啶基]-甲酮

BGJ398

3-(2,6-二氯-3,5-二甲氧基苯基)-1-[6-[[4-(4-乙基哌嗪-1-基)苯基]氨基]嘧啶-4-基]-1-甲基脲

BGJ398 (NVP-BGJ398);BGJ-398; BGJ 398; NVP BGJ398;CS-218;NVP-BGJ398; BGJ398; BGJ-398;INFIGRATINIB;BGJ 398;3-(2,6-二氯-3,5-二甲氧基苯基)-1-[6-[[4-(4-乙基哌嗪-1-基)苯基]氨基]嘧啶-4-基]-1-甲基脲

AMG 208

AMG 208

AMG208;AMG 208;CS-191;7-甲氧基-4-[(6-苯基-1,2,4-三唑并[4,3-B]哒嗪-3-基)甲氧基]喹啉;AMG-208;AMG208;AMG 208

PKI-402

PKI-402

PKI-402;1-[4-[3-乙基-7-(吗啉-4-基)-3H-[1,2,3]三唑并[4,5-D]嘧啶-5-基]苯基]-3-[4-[(4-甲基哌嗪-1-基)羰基]苯基]脲;PKI-402;PKI402

JTC-801

N-(4-氨基-2-甲基-6-喹啉基)-2-[(4-乙基苯氧基)甲基]苯甲酰胺盐酸盐

N-(4-氨基-2-甲基-6-喹啉基)-2-[(4-乙基苯氧基)甲基]苯甲酰胺盐酸盐;CS-161

(Z)-but-2-enedioic acid,cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone

环丙基[4-[3-(1H-咪唑-4-基)丙氧基]苯基]甲酮马来酸盐

FUB 359 MALEATE;FUB359 MALEATE;FUB-359 MALEATE;CS-109;马来酸盐形式;CIPROXIFAN 马来酸盐;环丙基[4-[3-(1H-咪唑-4-基)丙氧基]苯基]甲酮马来酸盐

LY2109761

LY2109761

4-[5,6-二氢-2-(2-吡啶基)-4H-吡咯并[1,2-B]吡唑-3-基]-7-[2-(4-吗啉基)乙氧基]喹啉;N-CYCLOPENTYL-Β-ALANINE;4-[5,6-二氢-2-(2-吡啶)-4H-吡咯并[1,2-B]吡唑-3-基]-7-[2-(4-吗啉)乙氧基]喹啉;LY2109761,一种新型的,选择性TGF-Β RECEPTOR TYPE I;II (TΒRI;II)双重抑制剂;CS-101

AS-605240

5-(6-喹喔啉亚甲基)-2,4-噻唑啉二酮

5-(6-喹噁啉YL亚甲基)-2,4-噻唑烷二酮;4-噻唑啉二酮;5-(6-喹喔啉亚甲基)-2;AS-605240,一种特异的 PI3KΓ 抑制剂;5-(6-喹喔啉亚甲基)-2,4-噻唑啉二酮

Nitisinone

尼替西农

尼替西农杂质;NTBC;NITISONE;SC0735;ORFADIN;CS-99;尼替西农;2-(2-硝基-4-三氟甲基苯甲酰基)-1,4-环己二酮

(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione

(3R,4R)-3-(5,6-二氢-4H-吡咯并[3,2,1-IJ]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮

ARQ197;ARQ-197;ARQ 197;(3R,4R)-3-(5,6-二氢-4H-吡咯并[3,2,1-IJ]喹啉)-4-(1H-吲哚)-2,5-吡咯烷二酮;TIVANTINIB ARQ-197

AZ628

AZ 628

AZ-628;CAS 878739-06-1;AZ 628;AZ628;CS-70;3-(1-氰基-1-甲基乙基)-N-[3-[(3,4-二氢-3-甲基-4-氧代-6-喹唑啉基)氨基]-4-甲基苯基]苯甲酰胺

LY315920 (Varespladib)

伐瑞拉迪

伐瑞拉迪;CS-68;CS-2393;伐瑞拉迪>98%;伐瑞拉地